MiMedx Group (NASDAQ:MDXG) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of MiMedx Group (NASDAQ:MDXG) in a research note released on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $11.00 price target on the stock.

MDXG has been the topic of a number of other research reports. Lake Street Capital assumed coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They issued a buy rating and a $12.00 price target on the stock. HC Wainwright reissued a buy rating and set a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. Finally, StockNews.com raised MiMedx Group from a buy rating to a strong-buy rating in a research report on Monday, June 3rd. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, MiMedx Group has a consensus rating of Buy and a consensus price target of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $6.78 on Tuesday. The company has a 50 day simple moving average of $7.16 and a two-hundred day simple moving average of $7.63. MiMedx Group has a fifty-two week low of $5.57 and a fifty-two week high of $9.27. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of 15.41 and a beta of 1.99. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.71 and a current ratio of 3.29.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.03. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. The company had revenue of $84.71 million during the quarter, compared to analyst estimates of $79.36 million. Analysts expect that MiMedx Group will post 0.34 EPS for the current fiscal year.

Institutional Trading of MiMedx Group

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of MiMedx Group by 4.1% during the third quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock valued at $46,927,000 after acquiring an additional 250,812 shares in the last quarter. Cannell Capital LLC increased its position in shares of MiMedx Group by 9.1% in the fourth quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock valued at $21,758,000 after buying an additional 207,207 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of MiMedx Group by 5.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,134,213 shares of the company’s stock worth $9,947,000 after buying an additional 57,704 shares during the period. Russell Investments Group Ltd. lifted its position in shares of MiMedx Group by 5.0% during the 1st quarter. Russell Investments Group Ltd. now owns 551,546 shares of the company’s stock valued at $4,247,000 after buying an additional 26,487 shares in the last quarter. Finally, Hillsdale Investment Management Inc. increased its holdings in MiMedx Group by 8.6% in the 1st quarter. Hillsdale Investment Management Inc. now owns 486,500 shares of the company’s stock worth $3,746,000 after acquiring an additional 38,600 shares in the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.